Revolution Medicines and Iambic Therapeutics have formed a multi-year alliance leveraging Iambic’s AI-based drug discovery platforms. The collaboration focuses on applying NeuralPLexer, a high-accuracy protein-ligand interaction model, to Revolution's proprietary molecular libraries to accelerate identification of novel oncology drug targets, particularly those difficult to address with traditional methods. Iambic may earn up to $25 million through upfront and milestone payments, with both partners retaining rights to select exclusive targets. This partnership exemplifies the growing integration of advanced AI in accelerating preclinical cancer therapeutic innovation.